Unveiling 6 Analyst Insights On Intellia Therapeutics
Analysts' ratings for Intellia Therapeutics (NASDAQ:NTLA) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.0, a high estimate of $120.00, and a low estimate of $29.00. Observing a downward trend, the current average is 8.16% lower than the prior average price target of $68.60.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Intellia Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joon Lee | Truist Securities | Maintains | Buy | $120.00 | $120.00 |
| Rick Bienkowski | Cantor Fitzgerald | Maintains | Overweight | $65.00 | $65.00 |
| Rick Bienkowski | Cantor Fitzgerald | Maintains | Overweight | $65.00 | $65.00 |
| David Lebowitz | Citigroup | Lowers | Neutral | $29.00 | $31.00 |
| Kostas Biliouris | BMO Capital | Raises | Outperform | $70.00 | $62.00 |
| David Nierengarten | Wedbush | Maintains | Neutral | $29.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Intellia Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Intellia Therapeutics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Intellia Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Intellia Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Intellia Therapeutics analyst ratings.
Unveiling the Story Behind Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Understanding the Numbers: Intellia Therapeutics's Finances
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Intellia Therapeutics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 129.53%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Intellia Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -371.3%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Intellia Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -10.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Intellia Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -8.39%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Intellia Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.